ArticleMedScience2026
Novel KMT2A fusion partner genes in acute leukemia-MRTFB, SORBS1, and SSC5D.
Article in MedScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
KMT2A (formerly MLL) gene rearrangements are common and clinically significant in acute leukemias, with outcomes influenced by the fusion partner. Over 100 fusion partners are known, but new ones continue to emerge. This study identified three novel partners-myocardin-related transcription factor B (MRTFB), sorbin and SH3 domain-containing 1 (SORBS1), and scavenger receptor cysteine-rich family member with 5 domains (SSC5D)-in pediatric and adult acute leukemia cases. Three cases were analyzed: a boy with B-cell precursor acute lymphoblastic leukemia, a girl with acute myelomonocytic leukemia, and a woman with therapy-related acute myeloid leukemia (AML). Diagnostics included cytogenetic analysis, fluorescence in situ hybridization (FISH), multiplex reverse transcription-polymerase chain reaction (RT-PCR), whole genome sequencing (WGS), and confirmation of breakpoints by Sanger sequencing, with validation at DNA and RNA levels, using patient-specific primers. WGS identified three novel in-frame fusions: KMT2A::MRTFB, KMT2A::SORBS1, and KMT2A::SSC5D, all within the major KMT2A breakpoint region. All patients achieved complete remission with tailored therapy, including chemotherapy and hematopoietic stem cell transplantation where indicated. Follow-up demonstrated durable remissions ranging from 9 to 23 months at the time of reporting. This study expands the catalog of KMT2A fusion partners, highlighting MRTFB, SORBS1, and SSC5D as novel leukemia-associated genes. The findings underscore the value of WGS for comprehensive detection of rare genetic events, enabling improved molecular classification and prognostic assessment in KMT2A-rearranged leukemias.
Indexed as
Identifiers
42467363What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.